Chimeric Antigen Receptor T-cell (CAR-T) Therapy

rawan239

2 years ago

The Department of Biotechnology supported the first CAR-T cell therapy performed at ACTREC at Tata Hospital in Mumbai.

The first CAR-T cell therapy was performed in June 2021 at the Bone Marrow Transplant unit at ACTREC, Tata Memorial Centre in Mumbai.

This is a first in India gene therapy that is in the early stages of a pilot clinical trial.The trial was conducted by IIT Bombay and Tata Memorial Hospital, Mumbai partly supported by the BIRAC-PACE scheme.

The central government’s National

d="M549.7 124.1c-6.3-23.7-24.8-42.3-48.3-48.6C458.8 64 288 64 288 64S117.2 64 74.6 75.5c-23.5 6.3-42 24.9-48.3 48.6-11.4 42.9-11.4 132.3-11.4 132.3s0 89.4 11.4 132.3c6.3 23.7 24.8 41.5 48.3 47.8C117.2 448 288 448 288 448s170.8 0 213.4-11.5c23.5-6.3 42-24.2 48.3-47.8 11.4-42.9 11.4-132.3 11.4-132.3s0-89.4-11.4-132.3zm-317.5 213.5V175.2l142.7 81.2-142.7 81.2z"/> Subscribe on YouTube

Biopharma Mission-BIRAC has approved 19.15 Cr for the team to conduct a first-in-human phase-1/2 clinical trial of the CAR-T cells.

Chimeric Antigen Receptor T-cell Therapy:

It is a type of treatment in which a patient’s T cells (a type of immune system cell) are altered in the laboratory to attack cancer cells.

T cells are extracted from the patient’s blood. Then, in the laboratory, the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells.

The unique receptor is known as a chimeric antigen receptor (CAR). A large number of CAR T cells are grown in the laboratory and infused into the patient.

It is used to treat certain types of blood cancers and is being researched for other cancers as well.